This year, AbbVie has continually been a big spender in the TV ad drug stakes, and it’s showing no signs of slowing down. After launching two new Rinvoq commercials this summer, the Big Pharma is now ...

Skyrizi has knocked Dupixent off its pedestal and claimed the top spot for ad impressions by Rx and over-the-counter (OTC) brands in April. The treatment for Crohn’s disease, psoriasis and psoriatic ...

As we hit the middle of the year, AbbVie is comfortably back in the top TV drug ad spenders’ driving seat taking the top two spots in July with its immunology blockbuster duo Skyrizi and Rinvoq, ...

The season of Skyrizi continues as the treatment for psoriasis, Crohn’s disease and psoriatic arthritis from AbbVie notched the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands.

CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for immunology powerhouses Skyrizi and Rinvoq by $4 billion. The company now projects more than $31 ...

Although AbbVie's blockbuster treatment Humira (adalimumab) will see biosimilar competition this year, the company expects that Rinvoq (upadacitinib) and Skyrizi (risankizumab) will eventually see ...

The approval was based on data from two phase 3 induction studies, and one phase 3 maintenance study. The Food and Drug Administration (FDA) has approved Skyrizi ® (risankizumab-rzaa) for the ...